Patents by Inventor Angray Kang

Angray Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7985841
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: July 26, 2011
    Assignee: The Scripps Research Institute
    Inventors: Angray Kang, Carlos F. Barbas, Richard A. Lerner
  • Publication number: 20060257856
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Application
    Filed: December 22, 2005
    Publication date: November 16, 2006
    Applicant: The Scripps Research Institute
    Inventors: Angray Kang, Carlos Barbas, Richard Lerner
  • Publication number: 20060246079
    Abstract: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided.
    Type: Application
    Filed: January 21, 2005
    Publication date: November 2, 2006
    Inventors: Phillip Morrow, Jeanne Morrow, Angray Kang, Fei Wang, Ivy Jiang, Ritsuko Sawada, Wolfgang Scholz
  • Patent number: 7118866
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: October 10, 2006
    Assignee: The Scripps Research Institute
    Inventors: Angray Kang, Carlos F. Barbas, III, Richard A. Lerner
  • Publication number: 20050281830
    Abstract: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided.
    Type: Application
    Filed: January 24, 2005
    Publication date: December 22, 2005
    Inventors: Phillip Morrow, Jeanne Morrow, Angray Kang, Fei Wang, Ivy Jiang, Ritsuko Sawada, Wolfgang Scholz
  • Publication number: 20040002057
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Application
    Filed: October 18, 2002
    Publication date: January 1, 2004
    Applicant: The Scripps Research Institute
    Inventors: Angray Kang, Carlos F. Barbas, Richard A. Lerner
  • Patent number: 6468738
    Abstract: Filamentous phage comprising a matrix of cpvIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: October 22, 2002
    Assignee: The Scripps Research Institute
    Inventors: Angray Kang, Carlos Barbas, Richard A. Lerner
  • Patent number: 6235469
    Abstract: Filamentous phase comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: May 22, 2001
    Assignee: The Scripps Research Institute
    Inventors: Angray Kang, Carlos Barbas, Richard A. Lerner
  • Patent number: 5955341
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an autogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a cpVIII membrane anchor domain fused to at least on of the polypeptides.
    Type: Grant
    Filed: February 2, 1995
    Date of Patent: September 21, 1999
    Assignee: The Scripps Research Institute
    Inventors: Angray Kang, Carlos Barbas, Richard Lerner
  • Patent number: 5658727
    Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: August 19, 1997
    Assignee: The Scripps Research Institute
    Inventors: Carlos Barbas, Angray Kang, Richard A. Lerner